Traders sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading on Tuesday. $88.73 million flowed into the stock on the tick-up and $138.30 million flowed out of the stock on the tick-down, for a money net flow of $49.57 million out of the stock. Of all companies tracked, Johnson & Johnson had the 0th highest net out-flow for the day. Johnson & Johnson traded up $0.88 for the day and closed at $119.92

A number of research firms have issued reports on JNJ. Standpoint Research began coverage on Johnson & Johnson in a report on Friday, May 20th. They set a “sell” rating and a $94.00 price objective on the stock. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price objective on the stock in a report on Monday, August 22nd. Barclays PLC reissued an “overweight” rating and set a $125.00 price objective (up previously from $120.00) on shares of Johnson & Johnson in a report on Sunday, July 10th. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price objective on the stock in a report on Friday, August 5th. Finally, BTIG Research lowered Johnson & Johnson from a “buy” rating to a “neutral” rating in a report on Thursday, May 12th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $119.53.

The company has a market capitalization of $326.86 billion and a price-to-earnings ratio of 22.26. The company has a 50 day moving average price of $122.75 and a 200 day moving average price of $114.75.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.68 by $0.06. The company had revenue of $18.50 billion for the quarter, compared to analyst estimates of $17.98 billion. Equities analysts anticipate that Johnson & Johnson will post $6.69 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, August 19th. Investors of record on Friday, August 5th were given a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a yield of 0.97%.

In other Johnson & Johnson news, VP Dominic J. Caruso sold 41,146 shares of the firm’s stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total value of $5,143,661.46. Following the sale, the vice president now owns 157,819 shares of the company’s stock, valued at approximately $19,728,953.19. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Ronald A. Kapusta sold 2,935 shares of the firm’s stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total value of $366,904.35. Following the completion of the sale, the chief accounting officer now directly owns 28,660 shares in the company, valued at approximately $3,582,786.60. The disclosure for this sale can be found here.

Other large investors have modified their holdings of the company. Dimensional Fund Advisors LP increased its stake in shares of Johnson & Johnson by 4.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 5,975,223 shares of the company’s stock worth $613,820,000 after buying an additional 275,499 shares in the last quarter. American International Group Inc. increased its stake in shares of Johnson & Johnson by 2.9% in the fourth quarter. American International Group Inc. now owns 1,543,576 shares of the company’s stock worth $158,556,000 after buying an additional 43,388 shares in the last quarter. King Luther Capital Management Corp increased its stake in shares of Johnson & Johnson by 6.9% in the fourth quarter. King Luther Capital Management Corp now owns 945,503 shares of the company’s stock worth $97,122,000 after buying an additional 60,862 shares in the last quarter. GAM Holding AG increased its stake in shares of Johnson & Johnson by 3.0% in the fourth quarter. GAM Holding AG now owns 677,515 shares of the company’s stock worth $69,594,000 after buying an additional 19,851 shares in the last quarter. Finally, KBC Group NV increased its stake in shares of Johnson & Johnson by 23.2% in the fourth quarter. KBC Group NV now owns 608,956 shares of the company’s stock worth $62,552,000 after buying an additional 114,649 shares in the last quarter.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.